Pomalidomide (Pomalyst®)


Indications for Prior Authorization:

  • Treatment of adult patients with multiple myeloma

Patients must meet the following criteria for the indication(s) above:

  • Patients must have received two prior therapies including lenalidomide (Revlimid®) and bortezomib (Velcade®) and have had disease progression within 60 days of completion of the last therapy

The Following Conditions Do Not Meet the Criteria for Use as Established by the WHA P & T Committee:

  • All non-FDA approved uses not listed in the approved indications
  • Patient must be pregnant or attempting to become pregnant

Recommended Dosing:

  • The recommended dose is 4 mg once daily on days one to 21 of a repeated 28 day cycle

Box warnings:

  • Embryo-fetal toxicity, venous thrombosis


One year


Last review date: December 2, 2013

The site you are transferring to is not hosted by WHA. WHA's Terms of Use and internet Privacy Practices do not apply to your use of this linked site. Please review the policies on privacy and terms of use for the linked site. WHA does not control the accuracy, completeness, or timeliness of the content on the linked site.